Is Abeona Therapeutics Inc. a good investment? Abeona Therapeutics Inc. (ABEO) is currently trading at 4.22 USD. Market analysts have a consensus price target of 18.88 USD. This suggests a potential upside from current levels.
In terms of valuation, the stock trades at a P/E ratio of 7.60. This relatively low multiple may signal that Abeona Therapeutics Inc. is undervalued compared to historical market norms.
Earnings Schedule: Abeona Therapeutics Inc. is expected to release its next earnings report on Nov. 11, 2026. The market consensus estimate for Forward EPS is -0.21.
No, it does not currently pay a dividend.
Abeona Therapeutics Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.
The next earnings date is projected to be Nov. 11, 2026. The company currently has a trailing EPS of -1.18.
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in Cleveland, Ohio.
| Year | Total Dividends |
|---|---|
| ▸2000 |
3,706.84 USD
|
| March 31, 2000 | 0.5930 |
| March 31, 2000 | 3,706.2500 |
| Split Date | Split Ratio to 1 |
|---|---|
| April 16, 1992 | 1:2 |
| June 5, 1998 | 1 |
| June 18, 1998 | 1:20 |
| June 5, 2006 | 1:5 |
| Oct. 24, 2014 | 1:50 |
| July 5, 2022 | 1:25 |
Community Discussion